Tonix Pharmaceuticals To Start Mid-Stage Long COVID Trial In Q4

Tonix Pharmaceuticals Holding Corp TNXP received the official minutes from a Type B pre-Investigational New Drug Application (IND) meeting with the FDA.
The meeting was related to TNX-102 SL1 (cyclobenzaprine HCl sublingual tablets) as a potential treatment for Long COVID Syndrome (Long COVID), which is now known officially as Post-Acute Sequelae of COVID-19 (PASC2).
Related: Tonix Pharma To Test Its Fibromyalgia Candidate In Long COVID Syndrome.
Tonix plans to submit the IND in Q4 of 2021 to support a Phase 2 study in a subset of Long COVID patients whose symptoms overlap with fibromyalgia.
Also Read: IDMC Recommends Tonix Pharma To Stop Enrollment In Fibromyalgia Trial.
Related content: Benzinga's Full FDA Calendar.
Price Action: TNXP shares are up 16.1% at $0.80 during the premarket session on the last check Tuesday.